September 29, 2022
Article
Srdan Verstovsek, MD, PhD, highlighted recent advancements in developing novel therapeutic strategies for myelofibrosis during SOHO 2022.
October 15, 2020
Article
Building on the transformative impetus from the first FDA-approved JAK 1/2 inhibitor, ruxolitinib, in the clinical landscape of myeloproliferative neoplasms, we are entering a new era of multiple JAK inhibitors and other diverse classes of drugs in rapid clinical development.